Bicara Therapeutics Inc. (BCAX) announced the pricing of its initial public offering of 17.50 million shares of its common stock at a public offering price of $18.00 per share.Bicara Therapeutics' shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol 'BCAX.' The offering is expected to close on September 16, 2024.In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2.625 million shares of its common stock at the public offering price, less underwriting discounts and commissions.

Bicara Therapeutics Inc.（BCAX）宣布首次公开发行1750万股普通股，发行价格为每股18.00美元。Bicara Therapeutics的股票预计将于2024年9月13日在纳斯达克全球市场开始交易，股票代码为“BCAX”本次发行预计于2024年9月16日结束。此外，Bicara Therapeutics已授予承销商30天的期权，以公开发行价格（扣除承销折扣和佣金）购买多达262.5万股普通股。

All of the shares of common stock are being offered by Bicara Therapeutics..

所有普通股均由Bicara Therapeutics提供。。

Bicara Therapeutics said it expects the gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bicara Therapeutics, to be about $315.00 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock.

Bicara Therapeutics表示，在扣除承销折扣和佣金以及Bicara Therapeutics应付的其他发行费用之前，预计首次公开募股的总收益约为3.1500亿美元，不包括承销商行使购买额外普通股的期权。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局决定生物技术股